Tecogen Inc. (TGEN) Stock Price & Analysis

Tecogen Inc. (TGEN) fell 5.29% to USD 3.22 as of July 25, 2026 at 05:33 UTC, according to Nexqual real-time market data.

TGEN last closed at USD 3.4; the session ranged USD 3.15–3.38 on volume of 336,988 shares. Market capitalization is $96.34M, with a 52-week range of USD 1.94–12.07 (ASE). Source: Nexqual, July 25, 2026 at 05:33 UTC.

Key Statistics (as of July 25, 2026 at 05:33 UTC)

PriceUSD 3.22
Change▼ 5.29% (down)
Previous CloseUSD 3.4
OpenUSD 3.38
Day RangeUSD 3.15 – 3.38
52-Week RangeUSD 1.94 – 12.07
Volume336,988 shares
Market Cap$96.34M
ExchangeASE

Technical Analysis (TGEN)

Nexqual's technical model rates TGEN "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:33 UTC.

Overall SignalSELL
RSI (14)25.84 (oversold)
vs SMA50Below (USD 5.21)
MACD-0.52 (negative)

Analyst Ratings (TGEN)

Wall Street analysts rate TGEN "Strong Buy" based on 3 analysts, with a mean price target of USD 8.83 (range USD 7.5–10), per Nexqual as of July 25, 2026 at 05:33 UTC.

Consensus RatingStrong Buy
Analyst Count3
Mean TargetUSD 8.83
High TargetUSD 10
Low TargetUSD 7.5
Buy / Hold / Sell3 / 0 / 0

Earnings (TGEN)

Next Earnings Date2026-08-12
EPS EstimateUSD -0.08
Revenue Estimate$5.85M

Recent Earnings History

QuarterActual vs Estimate
2025-12-31USD -0.1 vs est -0.1 ▲ beat
2025-09-30USD -0.07 vs est -0.05 ▼ miss

Source: Nexqual, July 25, 2026 at 05:33 UTC.

Financials & Fundamentals (TGEN)

Total Revenue$26.13M
Revenue Growth (YoY)-12.90%
Gross Margin+35.18%
Operating Margin-33.67%
Profit Margin-37.16%
ROE-66.83%
Debt / Equity14.61
Current Ratio3.02
Total Cash$9.33M
Total Debt$2.86M
Free Cash Flow$-11.05M

Source: Nexqual, July 25, 2026 at 05:33 UTC.

Financial Health Score (TGEN)

Nexqual rates Tecogen Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:33 UTC.

GrowthCritical — Revenue -13% YoY (latest Q), sharp decline
ProfitabilityWeak — Not yet profitable — scaling phase
Balance SheetStrong — $9M cash vs $3M debt, net cash position
Cash FlowWeak — FCF negative: -$11M, burning cash
EfficiencyCritical — ROE -67%, ROA -16.9%

Ownership (TGEN)

Insider Ownership+39.97%
Institutional Ownership+33.65%
Shares Outstanding29.92M
Float16.56M
Short % of Float+5.38%

Source: Nexqual, July 25, 2026 at 05:33 UTC.

Leadership (TGEN)

Tecogen Inc. is led by Abinand Rangesh (age 39), CEO & Director, per Nexqual as of July 25, 2026 at 05:33 UTC.

CEO & DirectorAbinand Rangesh (age 39)
President & COORobert A. Panora (age 71)
CFO, Treasurer & Chief Accounting OfficerRoger P. Deschenes (age 66)
Vice President of Business DevelopmentStephen Lafaille (age 37)

Major Backers & Investors (TGEN)

Notable institutional backers of Tecogen Inc. include Fidelity, Bard Associates Inc., Clear Harbor Asset Management, LLC, according to Nexqual as of July 25, 2026 at 05:33 UTC.

Active Investors

InvestorStake
Fidelity3.57%
Bard Associates Inc.2.75%
Clear Harbor Asset Management, LLC2.6%
Portolan Capital Management, LLC1.78%
Herald Investment Management Ltd1.68%
Arosa Capital Management LP1.4%
Palisades Investment Partners, LLC1.34%
UBS Group AG1.28%

Index Funds (Passive)

FundStake
Vanguard Group6.08%

Source: Nexqual, July 25, 2026 at 05:33 UTC.

From Tecogen Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)

Key Strengths & Strategy (as disclosed to the SEC)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
BIOMBiomolecular Life Holdings, Inc.USD 0.46▲ 0%
CASIFCASI Pharmaceuticals, Inc.USD 0.13▲ 0%
NGENNervGen Pharma Corp.USD 1.63▼ 5.23%
GNTAGenenta Science S.p.A.USD 1.59▼ 3.05%
VRAVera Bradley, Inc.USD 3.69▼ 4.16%

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:33 UTC. This page is informational and not investment advice.